177 related articles for article (PubMed ID: 36366851)
1. Physical Characterization and Safety Evaluation of Folic Acid-conjugated Mesoporous Silica Nanoparticles Loaded with Rhodojaponin III.
Yang Q; Zhao C; Yang J; Zhao J; Feng Y; Liu M; Zhang J
Curr Drug Deliv; 2023; 20(10):1559-1568. PubMed ID: 36366851
[TBL] [Abstract][Full Text] [Related]
2. Rhodojaponin III-Loaded Chitosan Derivatives-Modified Solid Lipid Nanoparticles for Multimodal Antinociceptive Effects in vivo.
Yang Q; Yang J; Sun S; Zhao J; Liang S; Feng Y; Liu M; Zhang J
Int J Nanomedicine; 2022; 17():3633-3653. PubMed ID: 35996527
[TBL] [Abstract][Full Text] [Related]
3. Folic acid modified lipid-bilayer coated mesoporous silica nanoparticles co-loading paclitaxel and tanshinone IIA for the treatment of acute promyelocytic leukemia.
Li Z; Zhang Y; Zhu C; Guo T; Xia Q; Hou X; Liu W; Feng N
Int J Pharm; 2020 Aug; 586():119576. PubMed ID: 32603839
[TBL] [Abstract][Full Text] [Related]
4. Folic acid-hydrophilic polymer coated mesoporous silica nanoparticles target doxorubicin delivery.
Al-Nadaf AH; Dahabiyeh LA; Jawarneh S; Bardaweel S; Mahmoud NN
Pharm Dev Technol; 2021 Jun; 26(5):582-591. PubMed ID: 33729906
[TBL] [Abstract][Full Text] [Related]
5. Etoposide encased folic acid adorned mesoporous silica nanoparticles as potent nanovehicles for enhanced prostate cancer therapy: synthesis, characterization, cellular uptake and biodistribution.
Saroj S; Rajput SJ
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S1115-S1130. PubMed ID: 30669865
[TBL] [Abstract][Full Text] [Related]
6. Controlled synthesis and size effects of multifunctional mesoporous silica nanosystem for precise cancer therapy.
Ma B; He L; You Y; Mo J; Chen T
Drug Deliv; 2018 Nov; 25(1):293-306. PubMed ID: 29334793
[TBL] [Abstract][Full Text] [Related]
7. Targeted anticancer prodrug with mesoporous silica nanoparticles as vehicles.
Fan J; Fang G; Wang X; Zeng F; Xiang Y; Wu S
Nanotechnology; 2011 Nov; 22(45):455102. PubMed ID: 22019849
[TBL] [Abstract][Full Text] [Related]
8. pH-Sensitive Delivery Vehicle Based on Folic Acid-Conjugated Polydopamine-Modified Mesoporous Silica Nanoparticles for Targeted Cancer Therapy.
Cheng W; Nie J; Xu L; Liang C; Peng Y; Liu G; Wang T; Mei L; Huang L; Zeng X
ACS Appl Mater Interfaces; 2017 Jun; 9(22):18462-18473. PubMed ID: 28497681
[TBL] [Abstract][Full Text] [Related]
9. Folic Acid-Polyethyleneimine Functionalized Mesoporous Silica Nanoparticles as a Controlled Release Nanocarrier.
Park J; Park SS; Jo NJ; Ha CS
J Nanosci Nanotechnol; 2019 Oct; 19(10):6217-6224. PubMed ID: 31026940
[TBL] [Abstract][Full Text] [Related]
10. Polyaspartic acid-anchored mesoporous silica nanoparticles for pH-responsive doxorubicin release.
Hakeem A; Zahid F; Zhan G; Yi P; Yang H; Gan L; Yang X
Int J Nanomedicine; 2018; 13():1029-1040. PubMed ID: 29497295
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Rhodojaponin III from Rhododendron molle G. Don on oral antinociceptive activity, mechanism of action, and subacute toxicity in rodents.
Yang J; Yang Q; Zhao J; Sun S; Liu M; Wang Y; Feng Y; Zhang J
J Ethnopharmacol; 2022 Aug; 294():115347. PubMed ID: 35533915
[TBL] [Abstract][Full Text] [Related]
12. Mesoporous silica nanoparticles: synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery.
Li Z; Zhang Y; Feng N
Expert Opin Drug Deliv; 2019 Mar; 16(3):219-237. PubMed ID: 30686075
[TBL] [Abstract][Full Text] [Related]
13. Cancer-targeted and intracellular delivery of Bcl-2-converting peptide with functional macroporous silica nanoparticles for biosafe treatment.
Wu Y; Ge P; Xu W; Li M; Kang Q; Zhang X; Xie J
Mater Sci Eng C Mater Biol Appl; 2020 Mar; 108():110386. PubMed ID: 31923940
[TBL] [Abstract][Full Text] [Related]
14. pH-responsive and targeted delivery of chrysin via folic acid-functionalized mesoporous silica nanocarrier for breast cancer therapy.
Ghosh N; Kundu M; Ghosh S; Das AK; De S; Das J; Sil PC
Int J Pharm; 2023 Jan; 631():122555. PubMed ID: 36586636
[TBL] [Abstract][Full Text] [Related]
15. Mesoporous silica nanoparticles for therapeutic/diagnostic applications.
Jafari S; Derakhshankhah H; Alaei L; Fattahi A; Varnamkhasti BS; Saboury AA
Biomed Pharmacother; 2019 Jan; 109():1100-1111. PubMed ID: 30551360
[TBL] [Abstract][Full Text] [Related]
16. Folic acid-conjugated mesoporous silica particles as nanocarriers of natural prodrugs for cancer targeting and antioxidant action.
AbouAitah K; Swiderska-Sroda A; Farghali AA; Wojnarowicz J; Stefanek A; Gierlotka S; Opalinska A; Allayeh AK; Ciach T; Lojkowski W
Oncotarget; 2018 May; 9(41):26466-26490. PubMed ID: 29899871
[TBL] [Abstract][Full Text] [Related]
17. Preparation of RGD Peptide/Folate Acid Double-Targeted Mesoporous Silica Nanoparticles and Its Application in Human Breast Cancer MCF-7 Cells.
Yan H; You Y; Li X; Liu L; Guo F; Zhang Q; Liu D; Tong Y; Ding S; Wang J
Front Pharmacol; 2020; 11():898. PubMed ID: 32612532
[TBL] [Abstract][Full Text] [Related]
18. An injectable mesoporous silica-based analgesic delivery system prolongs the duration of sciatic nerve block in mice with minimal toxicity.
Wang H; Zhang Y; Xu X; Wang A
Acta Biomater; 2021 Nov; 135():638-649. PubMed ID: 34520884
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of quercetin loaded mesoporous silica nanoparticles to the breast cancer cells.
Sarkar A; Ghosh S; Chowdhury S; Pandey B; Sil PC
Biochim Biophys Acta; 2016 Oct; 1860(10):2065-75. PubMed ID: 27392941
[TBL] [Abstract][Full Text] [Related]
20. Dual-Targeting Multifuntional Mesoporous Silica Nanocarrier for Codelivery of siRNA and Ursolic Acid to Folate Receptor Overexpressing Cancer Cells.
Zheng G; Shen Y; Zhao R; Chen F; Zhang Y; Xu A; Shao J
J Agric Food Chem; 2017 Aug; 65(32):6904-6911. PubMed ID: 28771340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
